RCM
SPHS

Rotella Capital Management’s Sophiris Bio, Inc. SPHS Stock Holding History

Rotella Capital Management’s Portfolio SPHS Stock Details SPHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-11,510
Closed -$20K – 390
2015
Q4 		$20K Buy
+11,510
New +$17K 0.02% 389

Other funds holding SPHS

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AIM
Alambic Investment Management Belvedere, California $9.12M AUM 34.54% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Rotella Capital Management's SPHS Position: Q1 2016 in Review

Rotella Capital Management sold out of Sophiris Bio, Inc. (SPHS) in Q1 2016, closing a stake of 11,510 shares — an estimated $20K sold.

Rotella Capital Management first reported a position in SPHS in Q4 2015 and held it in 1 quarter. The position peaked at $20K in Q4 2015. 23 funds tracked by Wall St. Rank hold SPHS as of Q1 2016.

  • Rotella Capital Management reported no remaining Sophiris Bio, Inc. position as of Q1 2016 after selling out during the quarter.
  • Rotella Capital Management sold 11,510 Sophiris Bio, Inc. shares in Q1 2016, an estimated $20K.
  • Rotella Capital Management first reported a position in Sophiris Bio, Inc. in Q4 2015 and held it in 1 quarter.
  • Rotella Capital Management's Sophiris Bio, Inc. position peaked at $20K in Q4 2015.
  • 23 funds tracked by Wall St. Rank held Sophiris Bio, Inc. as of Q1 2016.

Based on Rotella Capital Management's 13F filing for Q1 2016, filed 13 May 2016.